QuantiFERON-TB Gold Plus: High Qualitative and Quantitative Agreement between Enzyme-Linked Immunosorbent Assay (ELISA) and Chemiluminescence Immunoassay (CLIA)

Villalta, Danilo; Martelli, Paola; Moratto, Anna; Ligato, E.; Giacomello, Roberto; Hachimi, Sara El Idrissi El

doi:10.1128/jcm.01436-20

Cited by 5 publications

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mycobacterium tuberculosis Complex

Rowlinson,

Musser,

Khare

2023

ClinMicroNow

View full text Add to dashboard Cite

Tuberculosis (TB) is caused by a group of closely related slowly growing mycobacteria, collectively named the Mycobacterium tuberculosis complex (MTBC). Members of the MTBC have undergone several taxonomic reclassifications, which has resulted in confusing nomenclature. Mycobacterial culture is currently considered the reference standard for MTBC detection. Until the early 1990s, typing of MTBC strains was limited to mycobacterial phage typing and drug resistance patterns, methods which have low discriminatory power that have been replaced by molecular genotypic methods. Antimicrobial susceptibility testing is a critical element of the MTBC laboratory workup. While cell‐based immunodiagnostics, such as tuberculin skin testing or interferon‐gamma release assays, can be used as part of establishing a diagnosis of active TB disease, they are mainly used as tests for latent TB infection and to determine exposure to TB.

show abstract

Mycobacterium tuberculosis Complex

Rowlinson,

Musser,

Khare

2023

ClinMicroNow

View full text Add to dashboard Cite

show abstract

Self‐Blockade of PD‐L1 with Bacteria‐Derived Outer‐Membrane Vesicle for Enhanced Cancer Immunotherapy

Pan

Shao

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

The checkpoint inhibitor therapy that blocks programmed death‐1 (PD‐1) and its major ligand PD‐L1 has achieved encouraging clinical efficacy in certain cancers. However, the binding of checkpoint inhibitors with other immune cells that express PD‐L1 often results in a low response rate to the blockade and severe adverse effects. Herein, an LyP1 polypeptide‐modified outer‐membrane vesicle (LOMV) loaded with a PD‐1 plasmid is developed to achieve self‐blockade of PD‐L1 in tumor cells. The nanocarriers accumulate in the tumor tissue through OMV‐targeting ability and are internalized into the tumor cells via the LyP1‐mediated target, subsequently delivering PD‐1 plasmid into the nucleus, leading to the expression of PD‐1 by the tumor cells. In addition, a magnetic particle chemiluminescence kit is developed to quantitatively detect the binding rate of PD‐1/PD‐L1. The self‐expressed PD‐1 bonded with the PD‐L1 is expressed by both autologous and neighboring tumor cells, achieving self‐blockade. Simultaneously, the outer‐membrane protein of LOMV recruits cytotoxic lymphocyte cells and natural killer cells to tumor tissues and stimulates them to secrete IFN‐γ , improving the antitumor activity of the PD‐1/PD‐L1 self‐blocking therapy.

show abstract